Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors
Pharmaceutics · 27.06.2023 · 15 (7) · 1840
DOI: 10.3390/pharmaceutics15071840 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 27.06.2023. Verfasst von Anh Thu Nguyen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for the detection and therapy of tumor hypoxia. Nitroimidazoles are bioreducible moieties that can be selectively reduced under hypoxic conditions covalently bind to intracellular macromolecules, and are trapped within hypoxic cells and tissues. Recently, there has been a strong motivation to develop PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazole moieties for the visualization and treatment of hypoxic tumors. In this review, we summarize the development of some novel PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazoles, as well as their physicochemical properties, in vitro cellular uptake values, in vivo biodistribution, and PET/SPECT imaging results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.
- Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea.
ORCID-Profile: Hee-Kwon Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Nguyen, A. T., & Kim, H. K. (2023). Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors. Pharmaceutics, 15(7), 1840. https://doi.org/10.3390/pharmaceutics15071840
Vancouver
Nguyen AT, Kim HK. Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors. Pharmaceutics. 2023;15(7):1840. doi:10.3390/pharmaceutics15071840
BibTeX
@article{Nguyen2023,
author = {Nguyen, Anh Thu and Kim, Hee-Kwon},
title = {Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {7},
pages = {1840},
doi = {10.3390/pharmaceutics15071840}
}
EUVIMED